 
                 Patent Grant
 Patent Grant
                     7587247
 7587247
                    1. Field of the Invention
The present invention relates to a device for treating heart failure. More specifically, the invention relates to a cardiac harness having electrodes for providing defibrillation and/or pacing/sensing therapies. The design of the cardiac harness provides electrodes integrated with the cardiac harness having an impedance that optimize the compatibility of the system with commercially available internal cardioverter defibrillators.
2. General Background and State of the Art
Cardiac harnesses, such as those disclosed in U.S. Ser. No. 10/704,376 (“the '376 application”), may be used to treat cardiac heart failure. The entire contents of the '376 application is incorporated herein by reference. To treat other heart failures, including cardiac arrhythmias, the cardiac harness of the '376 application may include electrodes that are connected to an implantable cardioverter defibrillator (“ICD”), which are well known in the art. Such electrodes are capable of delivering a defibrillating electrical shock from the ICD to the heart. These electrodes may also provide pacing/sensing functions to the heart to treat cardiac failures, including bradycardia and tachycardia.
It is desirable to have the cardiac harness with electrodes be compatible with commercially available ICDs and defibrillation capable cardiac resynchronization therapy (“CRT-D”) and pulse generators (“PG”), such as those from Guidant, Medtronic, and St. Jude Medical. In order to be compatible with these commercially available ICDs and CRT-D PGs the electrodes of the cardiac harness must have an appropriate electrical impedance. If the system (cardiac harness with electrodes connected to a power source) has an impedance that is too low, the system could become damaged. On the other hand, if the system has an impedance that is too high, the system may produce an insufficient amount of electric current to travel across the cardiac tissue to sufficiently depolarize a critical amount of cardiac tissue to result in termination of the fibrillating wavefronts. Therefore, what is needed is a cardiac harness having defibrillation and/or pacing/sensing capabilities, wherein the electrodes of the cardiac harness have an impedance that is within an appropriate range.
In accordance with the present invention, a system for treating the heart includes a cardiac harness configured to conform generally to at least a portion of a patient's heart. The system also includes at least one electrode associated with the cardiac harness and positioned proximate to an outer surface of the heart, and a power source in communication with the electrode. The electrode and power source are at least a part of an electrical circuit. The electrical circuit may also include a conductor in communication between the electrode and the power source or the electrode and power source may communicate wirelessly. In order to ensure that the electrical circuit will function properly, the electrical circuit has an impedance between approximately 10 ohms and approximately 120 ohms. It is even more preferred that the impedance range be between approximately 20 ohms and 80 ohms. The lower impedance range is dictated by the functionality of the power source or pulse generator. Having too low of an impedance (under 10 ohms) can damage the electrical circuit incorporated with the cardiac harness. The upper impedance limit is that which continues to provide an adequate defibrillation threshold (“DFT”).
Several alterations can be made to the system to increase its impedance and avoid falling under the lower impedance limit of 10 ohms. In one aspect, a dielectric material such as silicone rubber is disposed on a pericardial side of the electrode (side of electrode facing away from the heart), leaving an epicardial side of the electrode (side of electrode in contact with the heart) un-insulated. Insulating the pericardial side of the electrode increases the impedance of the system, and prevents the system from having an impedance that falls under the lower impedance limit.
In another aspect, the pitch of a normal electrode coil can be increased. Increasing the pitch of the electrode coil decreases its surface area, and consequently, increases the impedance of the system.
In yet another aspect of the present invention, the composition of the conductive wire or conductor, which may include an MP35N-Ag composite, can be altered by changing the silver content. The preferred balance of impedance and mechanical strength is achieved with a 25% silver content of the conductive wire composite. In order to keep the impedance of the present system above the lower impedance limit, the silver content within the conductor can be from 0% to about 50%.
Also, the cross-section of the wire forming the electrode can be reduced to increase the impedance. In this embodiment, changing the wire of the electrode in any way to reduce the area of its cross-section or its outer diameter will increase its impedance. The width and/or height of the cross-section of the wire forming the electrode can be reduced to decrease its cross sectional area. In another embodiment, the cross-sectional shape of the electrode coil wire may be changed to reduce its surface area. In one instance, the wire of the electrode can be changed from a rectangular cross-section to a circular cross-section.
Further, the overall outer diameter of the electrode can be reduced to increase the impedance of the system. If the electrode is in the form of a helical coil, the wire forming the coil can be wound tighter to decrease the overall outer diameter of the helical coil.
In a further aspect, a resistor can be plugged in-line with the lead system to increase the impedance of the system.
Another aspect includes an electrode with circumferentially insulating segments disposed along its length. The insulating segments can be formed of any dielectric material such as silicone rubber, and may be any size. Further, any number of insulating segments may be disposed along the electrode. The insulating segments disposed around the electrode reduce the exposed surface area of the electrode, thereby increasing the impedance. The insulating segments may also force a redistribution of current in the exposed regions of the electrode in order to optimize the DFT.
Another aspect includes an electrode with a resistive film (i.e., an oxide layer) disposed on the electrode surface. The resistive film could further be deposited non-uniformly so as to spatially modulate surface resistance (i.e., to reduce current density edge effects, or to alter the current distribution along the length of the electrode to optimize the DFT).
In yet another aspect, the length of the electrode can be shortened. By shortening the electrode, the overall surface area of the electrode is decreased, thereby increasing the impedance of the system.
    
    
    
    
    
    
    a is a cross-sectional view of a wire forming an electrode with reduced dimensions.
    
    b is a cross-sectional view of a wire forming an electrode with less cross-sectional area due to the change in the cross-sectional shape of the wire.
    
    
The present invention is directed to a cardiac harness system for treating the heart. The term “cardiac harness” as used herein is a device fit onto a patient's heart to apply a compressive force on the heart during at least a portion of the cardiac cycle. The cardiac harness system of the present invention couples a cardiac harness for treating the heart with a cardiac rhythm management device. More particularly, the cardiac harness includes rows or undulating strands of spring elements that provide a compressive force on the heart during diastole and systole in order to relieve wall stress pressure on the heart. Associated with the cardiac harness is a cardiac rhythm management device for treating any number of irregularities in heart beat due to, among other reasons, congestive heart failure. Thus, the cardiac rhythm management device associated with the cardiac harness can include one or more of the following: an implantable cardioverter defibrillator (“ICD”) with associated leads and electrodes; a cardiac pacemaker (or cardiac resynchronization therapy (“CRT”) pulse generator) including leads and electrodes used for sensing cardiac function and providing pacing stimuli to treat synchrony of both vessels; and a combined ICD and pacemaker (referred to as a (“CRT-D”)), with associated leads and electrodes to provide a defibrillation shock and/or pacing/sensing functions.
The cardiac harness system may include various configurations of panels connected together to at least partially surround the heart and assist the heart during diastole and systole. The cardiac harness system also includes one or more leads having electrodes associated with the cardiac harness and a source of electrical energy supplied to the electrodes for delivering a defibrillating shock or pacing stimuli.
In one embodiment of the invention, as shown in 
In the embodiment shown in 
As best shown in 
The cardiac harness 10 may be produced in a range of sizes, with distinct lengths depending on the size and the number or rows of undulating strands 14. In the embodiment shown in 
In one embodiment, the cardiac harness 10 is intended to function with commercially available pace/sense leads and ICD pulse generators. To ensure the cardiac harness is compatible with commercially available ICD and CRT-D pulse generators, it must have an appropriate electrical impedance. Commercially available ICD and CRT-D pulse generators, such as those from Guidant, Medtronic, and St. Jude Medical, typically have a lower impedance limit below which the device will not deliver a shock during programmed device testing at implantation. This limit, typically 20Ω, is dictated by the current carrying limits of the internal pulse generator circuitry. Since the ICD delivers a set voltage from a charged capacitor, as the system impedance drops, the delivered current increases. Once implanted, the ICD should deliver a defibrillation shock even if the impedance drops below 20Ω, although there is a risk that the circuitry of the system will be damaged. Depending on the initial voltage, actual unit range of the lead system attached to the cardiac harness is no lower than about 20Ω, with a functional limit of about 10Ω.
Several parameters affect the system impedance. These include, but are not limited to, the inherent resistivity of the tissue volume through which the defibrillation current flows (may be affected by tissue density, tissue fluid levels, air volume, etc.); the distance between the electrodes attached to the cardiac harness; the surface area of the electrodes exposed to the body tissues; the electrode geometry (and impact on current edge effects); the inter-relationship between isopotential lines of current flow; the resistance in the lead electrodes, conductors, and contact junctions, and ICD or CRT-D circuitry; electrode material (polarization effects) and microscopic surface texture (i.e., fractal coatings, black Pt, etc.); and the morphology of the shock waveform (i.e., repolarization effects of a biphasic waveform).
As the length of the electrode 18 increases to extend along cardiac harnesses of varying lengths, the impedance of the system decreases. In other words, the larger cardiac harness have longer electrodes with more exposed surface area than the electrodes attached to smaller cardiac harnesses, and the electrical circuitry associated with the longer electrodes also have a lower impedance than the electrical circuitry associated with the smaller electrodes. Therefore, what is needed is a way to increase the impedance of the system to avoid falling under the lower impedance limit of 20Ω. In one embodiment as shown in the cross-sectional view of 
In another embodiment, the pitch of electrode coil 18 can be increased. The coil shown in 
In yet another embodiment, the composition of the conductive wire or conductor 20, which may include an MP35N-Ag composite, can be altered by changing the silver content. By specifying the silver content of the conductor to be around 25%, a preferred balance of impedance and mechanical strength of the lead system is achieved. In order to keep the impedance of the present system above the lower impedance limit, the silver content within the conductor can be from 0% to about 50%.
The cross-sectional dimensions of the wire forming the electrode coil 18 can be reduced to increase the impedance. In this embodiment, changing the wire of the electrode in any way to reduce the area of its cross-section or its outer diameter will increase impedance. The width and/or height of the wire forming the electrode coil can be reduced to decrease its cross sectional area as shown in 
In other embodiments, the overall outer diameter of the electrode can be reduced to increase the impedance of the system. If the electrode is in the form of a helical coil, the wire forming the coil can be wound tighter to decrease the overall outer diameter of the helical coil, and thereby decreasing the overall surface area of the electrode.
In a further embodiment, a resistor 40 can be plugged in-line with the lead system to increase the impedance of the system. 
Referring now to 
In another embodiment, the electrode 18 may include a resistive film (i.e., an oxide layer) disposed on at least a portion of its surface. The resistive film could further be deposited non-uniformly so as to spatially modulate surface resistance (i.e., to reduce current density edge effects, or to alter the current distribution along the length of the electrode to optimize the DFT). By disposing the resistive film along the surface of the electrode, the impedance of the system will increase.
In yet another embodiment, the length of the electrode 18 can be shortened. For example, the length of the electrode shown in 
The present system must also not exceed an upper impedance level. If the impedance of the system is too high, an insufficient amount of current will travel across the cardiac tissue to sufficiently depolarize a critical amount of cardiac tissue to result in termination of the fibrillating wavefronts. With biphasic waveforms, studies suggest that a voltage gradient of at least 3V/cm is required to achieve 80% defibrillation success. See Zhou X, Daubert J P, Wolf P D, Smith W M, Ideker R E; Epicardial Mapping Of Vetricular Defibrillation With Monophasic And Biphasic Shocks In Dogs; Circulation Research 72:145-160 (1993); which is hereby incorporated by reference. So, while there is no particular upper impedance limit, the impedance needs to be within a reasonable range to ensure defibrillation success. One way to define a reasonable upper limit is to first determine what impedance values are typical in commercially available devices that have acceptable DFT values.
The typical system shock impedance values seen in humans have been reported in various studies (see table shown in Appendix 1). The data from the table of Appendix 1 was gathered from the following references, also listed in Appendix 1; 1) Rinaldi A. C., Simon R. D., Geelen P., Reek S., Baszko A., Kuehl M., Gill J. S., A Randomized Prospective Study Of Single Coil Versus Dual Coil Defibrillation In Patients With Ventricular Arrhythmias Undergoing Implantable Cardioverter Defibrillator Therapy, Journal of Pacing and Clinical Electrophysiology 26:1684-1690 (2003); 2) Gold M R, Olsovsky M R, Pelini M A, Peters R W, Shorofsky S R, Comparison Of Single And Dual Coil Active Pectoral Defibrillation Lead Systems, Journal of the American College of Cardiology 1391-4 (1998); 3) Schulte B, Sperzel J, Carlsson J, Schwarz T, Ehrlich W, Pitschner H F, Neuzner J, Dual-Coil Vs. Single-Coil Active Pectoral Implantable Defibrillator Lead Systems: Defibrillation Energy Requirements And Probability Of Defibrillation Success At Multiples Of The Defibrillation Energy Requirements, Europace 3:177-180 (2001); 4) Sandstedt B, Kennergren C, Edvardsson N, Bidirectional Defibrillation Using Implantable Defibrillators: A Prospective Randomized Comparison Between Pectoral And Abdominal Active Generators, Journal of the American College of Cardiology 1343-1353 (2001); and 5) Shorofsky S R, Peters R W, Rashba E J, Gold M R, Comparison Of Step-Down And Binary Search Algorithms For Determination Of Defibrillation Threshold In Humans, Journal of Pacing and Clinical Electrophysiology 27:218-220 (2004). All of these references are herein incorporated by reference.
Based on the data from the above references, the mean impedance at implant for a dual coil active pectoral PG system is about 40Ω (standard deviation ranges 4-10Ω), and about 60Ω±10Ω for a single coil active PG system. The single (distal) coil used in these studies was about 50 mm long and had a surface area of about 450-480 mm2. The second (proximal) coil in the dual-coil systems was about 72 mm long and had a surface area of about 660-671 mm2.
To compare, a study in pigs was conducted to determine the DFT at the time of implantation of one embodiment of a cardiac harness having four rows of undulating strands and with 60° intra-electrode spacing. The electrodes incorporated with the cardiac harness used in this experiment had an exposed inner and outer coil surface with a surface area of about 660 mm2. The results from this study are presented in U.S. Ser. No. 11/051,823 (“the '823 application”), which is hereby incorporated by reference in its entirety. In one experiment, the a defibrillation vector for the defibrillating cardiac harness system was created from the right ventricular electrodes of the cardiac harness to the left ventricular electrodes of the cardiac harness and the active can coupled together. For this experiment, as listed in the '823 application, the mean DFT was 9.6 J and the impedance was measured at 27Ω. Also listed in the '823 application were comparable values for the mean DFT and impedance from a standard single lead defibrillation coil in the right ventricular endocardium, with a defibrillation vector from the defibrillation coil to the active can. The mean DFT was determined to be 19.3 J and the impedance was measured at 46Ω. Compared with the human data from a similar system reported in Appendix 1, the mean DFT values of the pig experiment with the defibrillation vector from the defibrillation coil disposed in the right ventricular endocardium to the active can are about 8 J higher and the impedance slightly lower. Also of note in the pig study was the advantage of increasing the intra-pair electrode spacing in lowering the mean DFT.
As with other commercially available epicardial patches and, to some extent, endocardial leads, it is anticipated that the impedance of the implant will change with time after implantation. See Schwartzman D, Hull M L, Callans D J, Gottlieb C D, Marchlinski F E; Serial Defibrillation Lead Impedance In Patients With Epicardial And Nonthoracotomy Lead Systems; Journal of Cardiovascular Electrophysiology 7:697-703 (1996), which is hereby incorporated by reference. Thus, when designing the cardiac harness implant to function with an ICD or CRT-D system, consideration of the time course of impedance change is important to ensure the system remains functional throughout the healing phase.
In order to test a cardiac harness having six-rows of undulating strands, additional bench-top tests were conducted in a saline tank with the cardiac harness including defibrillation electrodes placed over a saturated heart-shaped piece of foam (to mimic a human heart). Shock tests on a cardiac harness including defibrillation electrodes, which were exposed or un-insulated on both sides of the electrode, and having four-rows of undulating strands were performed. The defibrillation vector of this test simulated the vector from the right ventricular pair of electrodes to the left ventricular pair of electrodes coupled to the active can in the left pectoral region. During this test, the impedance was measured at about 26Ω (similar to the pig data referenced above). Repeating the test with the six-row cardiac harness including defibrillation electrodes with 600 intra-electrode spacing, and inner and outer coil surface exposed giving an electrode surface area of about 1060 mm2 per pair, resulted in an impedance of about 20Ω, which is less than the impedance of the smaller cardiac harness.
Because of the concern that the six-row cardiac harness including defibrillation electrodes would have an impedance too close to the lower limit of the ICD, the design of the cardiac harness was altered by adding silicone rubber insulation to the outside (pericardial side) of the electrodes, leaving only the inside surface (or epicardial side) exposed. This resulted in an exposed electrode surface area of the four-row and six-row pairs of 330 mm2 and 530 mm2, respectively. The expectation was that by reducing the electrode surface area, the impedance would increase. A repeat of the above in-vitro tests resulted in the four-row cardiac harness having its impedance increase from about 26Ω to about 39Ω, and the six-row cardiac harness having its impedance increase from about 20Ω to about 30Ω. A comparison of 60° and 45° intra electrode separation showed no significant difference in the impedance level.
While insulating the outside of the electrode was one way to increase impedance, other methods, such as those discussed above can also be used to increase or otherwise modify the system shock impedance.
Again, the lower impedance range is dictated by the functionality of the power source or pulse generator. This is preferably no lower than about 20Ω, with a functional limit of about 10Ω. The upper impedance limit is that which continues to provide an adequate DFT. Given the data in humans discussed above, the preferred upper impedance range is about 80Ω. However, as noted in the pig study, the cardiac harness with defibrillating electrode geometry may provide a more uniform distribution of current compared to commercial leads, and therefore may be able to provide adequate voltage gradients with higher impedance values than are reported with conventional electrodes. Thus, the functional impedance range is estimated to run about 50% higher, up to 120Ω. In summary, the preferred impedance range for the cardiac harness with lead system is about 20Ω to about 80Ω, with a functional range of about 10Ω to 120Ω.
Although the present invention has been described in terms of certain preferred embodiments, other embodiments that are apparent to those of ordinary skill in the art are also within the scope of the invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims. While the impedance values, electrode dimensions, types of materials and coatings described herein are intended to define the parameters of the invention, they are by no means limiting and are exemplary embodiments.
  
    
      
        
        
          
            
          
        
        
          
            
          
          
            
          
        
      
      
        
        
        
        
        
        
          
            
            
            
            
            
          
          
            
            
            
            
            
          
        
      
      
        
        
        
        
        
        
        
        
        
        
          
            
            
            
            
            
            
            
            
            
          
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
          
            
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
          
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
            
            
          
          
            
            
            
            
            
            
            
            
            
          
          
            
          
          
            
          
          
            
          
          
            
          
          
            
          
          
            
          
          
            
          
        
      
    
  
| Number | Name | Date | Kind | 
|---|---|---|---|
| 2278926 | Hartwell | Apr 1942 | A | 
| 2826193 | Vineberg | Mar 1958 | A | 
| 3464322 | Pequignot | Sep 1969 | A | 
| 3513836 | Sausse | May 1970 | A | 
| 3587567 | Schiff | Jun 1971 | A | 
| 3613672 | Schiff | Oct 1971 | A | 
| 3966401 | Hancock et al. | Jun 1976 | A | 
| 3983863 | Janke et al. | Oct 1976 | A | 
| 3988782 | Dardik et al. | Nov 1976 | A | 
| 4011947 | Sawyer | Mar 1977 | A | 
| 4048990 | Goetz | Sep 1977 | A | 
| 4065816 | Sawyer | Jan 1978 | A | 
| 4108161 | Samuels et al. | Aug 1978 | A | 
| 4192293 | Asrican | Mar 1980 | A | 
| 4211325 | Wright | Jul 1980 | A | 
| 4261342 | Aranguren Duo | Apr 1981 | A | 
| 4306318 | Mano et al. | Dec 1981 | A | 
| 4372293 | Vijil-Rosales | Feb 1983 | A | 
| 4403604 | Wilkinson et al. | Sep 1983 | A | 
| 4428375 | Ellman | Jan 1984 | A | 
| 4512471 | Kaster et al. | Apr 1985 | A | 
| 4536893 | Parravicini | Aug 1985 | A | 
| 4545783 | Vaughn | Oct 1985 | A | 
| 4628937 | Hess et al. | Dec 1986 | A | 
| 4630597 | Kantrowitz et al. | Dec 1986 | A | 
| 4665906 | Jervis | May 1987 | A | 
| 4690134 | Snyders | Sep 1987 | A | 
| 4697703 | Will | Oct 1987 | A | 
| 4750619 | Cohen et al. | Jun 1988 | A | 
| 4821723 | Baker et al. | Apr 1989 | A | 
| 4827932 | Ideker et al. | May 1989 | A | 
| 4834707 | Evans | May 1989 | A | 
| 4838288 | Wright et al. | Jun 1989 | A | 
| 4840626 | Linsky et al. | Jun 1989 | A | 
| 4863016 | Fong et al. | Sep 1989 | A | 
| 4878890 | Bilweis | Nov 1989 | A | 
| 4936857 | Kulik | Jun 1990 | A | 
| 4957477 | Lundbäck | Sep 1990 | A | 
| 4960424 | Grooters | Oct 1990 | A | 
| 4973300 | Wright | Nov 1990 | A | 
| 4976730 | Kwan-Gett | Dec 1990 | A | 
| 5031762 | Heacox | Jul 1991 | A | 
| 5057117 | Atweh | Oct 1991 | A | 
| 5067957 | Jervis | Nov 1991 | A | 
| 5087243 | Avitall | Feb 1992 | A | 
| 5098369 | Heilman et al. | Mar 1992 | A | 
| 5106386 | Isner et al. | Apr 1992 | A | 
| 5119804 | Anstadt | Jun 1992 | A | 
| 5131905 | Grooters | Jul 1992 | A | 
| 5150706 | Cox et al. | Sep 1992 | A | 
| 5169381 | Snyders | Dec 1992 | A | 
| 5186711 | Epstein | Feb 1993 | A | 
| 5190546 | Jervis | Mar 1993 | A | 
| 5192314 | Daskalakis | Mar 1993 | A | 
| 5197978 | Hess | Mar 1993 | A | 
| 5256132 | Snyders | Oct 1993 | A | 
| 5279539 | Bohan et al. | Jan 1994 | A | 
| 5290217 | Campos | Mar 1994 | A | 
| 5336254 | Brennen et al. | Aug 1994 | A | 
| 5344442 | Deac | Sep 1994 | A | 
| 5352184 | Goldberg et al. | Oct 1994 | A | 
| 5356432 | Rutkow et al. | Oct 1994 | A | 
| 5366460 | Eberbach | Nov 1994 | A | 
| 5383840 | Heilman et al. | Jan 1995 | A | 
| 5385156 | Oliva | Jan 1995 | A | 
| 5385229 | Bittmann et al. | Jan 1995 | A | 
| 5385528 | Wilk | Jan 1995 | A | 
| 5405360 | Tovey | Apr 1995 | A | 
| 5429584 | Chiu | Jul 1995 | A | 
| 5433727 | Sideris | Jul 1995 | A | 
| 5456711 | Hudson | Oct 1995 | A | 
| 5460962 | Kemp | Oct 1995 | A | 
| 5500015 | Deac | Mar 1996 | A | 
| 5507779 | Altman | Apr 1996 | A | 
| 5509428 | Dunlop | Apr 1996 | A | 
| 5524633 | Heaven et al. | Jun 1996 | A | 
| 5533958 | Wilk | Jul 1996 | A | 
| 5534024 | Rogers et al. | Jul 1996 | A | 
| 5545210 | Hess et al. | Aug 1996 | A | 
| 5558617 | Heilman et al. | Sep 1996 | A | 
| 5571215 | Sterman et al. | Nov 1996 | A | 
| 5582616 | Bolduc et al. | Dec 1996 | A | 
| 5584803 | Stevens et al. | Dec 1996 | A | 
| 5593424 | Northrup III | Jan 1997 | A | 
| 5593441 | Lichtenstein et al. | Jan 1997 | A | 
| 5597378 | Jervis | Jan 1997 | A | 
| 5603337 | Jarvik | Feb 1997 | A | 
| 5607477 | Schindler et al. | Mar 1997 | A | 
| 5647372 | Tovey et al. | Jul 1997 | A | 
| 5647380 | Campbell et al. | Jul 1997 | A | 
| 5695525 | Mulhauser et al. | Dec 1997 | A | 
| 5702343 | Alferness | Dec 1997 | A | 
| 5713954 | Rosenberg et al. | Feb 1998 | A | 
| 5727569 | Benetti et al. | Mar 1998 | A | 
| 5749839 | Kovacs | May 1998 | A | 
| 5782746 | Wright | Jul 1998 | A | 
| 5800334 | Wilk | Sep 1998 | A | 
| 5800528 | Lederman et al. | Sep 1998 | A | 
| 5814097 | Sterman et al. | Sep 1998 | A | 
| 5824028 | Knisley | Oct 1998 | A | 
| 5836311 | Borst et al. | Nov 1998 | A | 
| 5848962 | Feindt et al. | Dec 1998 | A | 
| 5849005 | Garrison et al. | Dec 1998 | A | 
| 5853422 | Huebsch et al. | Dec 1998 | A | 
| 5865791 | Whayne et al. | Feb 1999 | A | 
| 5904690 | Middleman et al. | May 1999 | A | 
| 5910124 | Rubin | Jun 1999 | A | 
| 5927284 | Borst et al. | Jul 1999 | A | 
| 5948019 | Shu et al. | Sep 1999 | A | 
| 5957977 | Melvin | Sep 1999 | A | 
| 5961440 | Schweich, Jr. et al. | Oct 1999 | A | 
| 5976069 | Navia et al. | Nov 1999 | A | 
| 5979456 | Magovern | Nov 1999 | A | 
| 5984857 | Buck et al. | Nov 1999 | A | 
| 5990378 | Ellis | Nov 1999 | A | 
| 6007486 | Hunt et al. | Dec 1999 | A | 
| 6015378 | Borst et al. | Jan 2000 | A | 
| 6024096 | Buckberg | Feb 2000 | A | 
| 6045497 | Schweich, Jr. et al. | Apr 2000 | A | 
| 6050936 | Schweich, Jr. et al. | Apr 2000 | A | 
| 6059715 | Schweich, Jr. et al. | May 2000 | A | 
| 6071303 | Laufer | Jun 2000 | A | 
| 6076013 | Brennan et al. | Jun 2000 | A | 
| 6077214 | Mortier et al. | Jun 2000 | A | 
| 6077218 | Alferness | Jun 2000 | A | 
| 6079414 | Roth | Jun 2000 | A | 
| 6085754 | Alferness et al. | Jul 2000 | A | 
| 6095968 | Snyders | Aug 2000 | A | 
| 6110100 | Talpade | Aug 2000 | A | 
| 6117159 | Huebsch et al. | Sep 2000 | A | 
| 6117979 | Hendriks et al. | Sep 2000 | A | 
| 6123662 | Alferness et al. | Sep 2000 | A | 
| 6125852 | Stevens et al. | Oct 2000 | A | 
| 6126590 | Alferness | Oct 2000 | A | 
| 6155968 | Wilk | Dec 2000 | A | 
| 6155972 | Nauertz et al. | Dec 2000 | A | 
| 6162168 | Schweich, Jr. et al. | Dec 2000 | A | 
| 6165119 | Schweich, Jr. et al. | Dec 2000 | A | 
| 6165120 | Schweich, Jr. et al. | Dec 2000 | A | 
| 6165121 | Alferness | Dec 2000 | A | 
| 6165122 | Alferness | Dec 2000 | A | 
| 6166184 | Hendriks et al. | Dec 2000 | A | 
| 6169922 | Alferness et al. | Jan 2001 | B1 | 
| 6174279 | Girard | Jan 2001 | B1 | 
| 6179791 | Krueger | Jan 2001 | B1 | 
| 6183411 | Mortier et al. | Feb 2001 | B1 | 
| 6190408 | Melvin | Feb 2001 | B1 | 
| 6193648 | Krueger | Feb 2001 | B1 | 
| 6206820 | Kazi et al. | Mar 2001 | B1 | 
| 6214047 | Melvin | Apr 2001 | B1 | 
| 6221103 | Melvin | Apr 2001 | B1 | 
| 6224540 | Ledermann et al. | May 2001 | B1 | 
| 6230714 | Alferness et al. | May 2001 | B1 | 
| 6260552 | Mortier et al. | Jul 2001 | B1 | 
| 6261222 | Schweich, Jr. et al. | Jul 2001 | B1 | 
| 6264602 | Mortier et al. | Jul 2001 | B1 | 
| 6282445 | Reinhardt et al. | Aug 2001 | B1 | 
| 6287250 | Peng et al. | Sep 2001 | B1 | 
| 6293906 | Vanden Hoek et al. | Sep 2001 | B1 | 
| 6306141 | Jervis | Oct 2001 | B1 | 
| 6360749 | Jayaraman | Mar 2002 | B1 | 
| 6375608 | Alferness | Apr 2002 | B1 | 
| 6390976 | Spence et al. | May 2002 | B1 | 
| 6402679 | Mortier et al. | Jun 2002 | B1 | 
| 6402680 | Mortier et al. | Jun 2002 | B2 | 
| 6406420 | McCarthy et al. | Jun 2002 | B1 | 
| 6409760 | Melvin | Jun 2002 | B1 | 
| 6416459 | Haindl | Jul 2002 | B1 | 
| 6425856 | Shapland et al. | Jul 2002 | B1 | 
| 6432039 | Wardle | Aug 2002 | B1 | 
| 6451025 | Jervis | Sep 2002 | B1 | 
| 6482146 | Alferness et al. | Nov 2002 | B1 | 
| 6517570 | Lau et al. | Feb 2003 | B1 | 
| 6537203 | Alferness et al. | Mar 2003 | B1 | 
| 6544168 | Alferness | Apr 2003 | B2 | 
| 6547821 | Taylor et al. | Apr 2003 | B1 | 
| 6564094 | Alferness et al. | May 2003 | B2 | 
| 6567699 | Alferness et al. | May 2003 | B2 | 
| 6569082 | Chin | May 2003 | B1 | 
| 6572533 | Shapland et al. | Jun 2003 | B1 | 
| 6575921 | Vanden Hoek et al. | Jun 2003 | B2 | 
| 6582355 | Alferness et al. | Jun 2003 | B2 | 
| 6587734 | Okuzumi | Jul 2003 | B2 | 
| 6595912 | Lau et al. | Jul 2003 | B2 | 
| 6602184 | Lau et al. | Aug 2003 | B2 | 
| 6612978 | Lau et al. | Sep 2003 | B2 | 
| 6612979 | Lau et al. | Sep 2003 | B2 | 
| 6645139 | Haindl | Nov 2003 | B2 | 
| 6663558 | Lau et al. | Dec 2003 | B2 | 
| 6673009 | Vanden Hoek et al. | Jan 2004 | B1 | 
| 6682474 | Lau et al. | Jan 2004 | B2 | 
| 6682475 | Cox et al. | Jan 2004 | B2 | 
| 6682476 | Alferness et al. | Jan 2004 | B2 | 
| 6685620 | Gifford, III et al. | Feb 2004 | B2 | 
| 6685627 | Jayaraman | Feb 2004 | B2 | 
| 6689048 | Vanden Hoek et al. | Feb 2004 | B2 | 
| 6695769 | French et al. | Feb 2004 | B2 | 
| 6701929 | Hussein | Mar 2004 | B2 | 
| 6702732 | Lau et al. | Mar 2004 | B1 | 
| 6723041 | Lau et al. | Apr 2004 | B2 | 
| 6730016 | Walsh et al. | May 2004 | B1 | 
| 6755779 | Vanden Hoek et al. | Jun 2004 | B2 | 
| 6876887 | Okuzumi | Apr 2005 | B2 | 
| 6881185 | Vanden Hock et al. | Apr 2005 | B2 | 
| 6887192 | Whayne et al. | May 2005 | B1 | 
| 6893392 | Alferness | May 2005 | B2 | 
| 6896652 | Alferness et al. | May 2005 | B2 | 
| 6902522 | Walsh et al. | Jun 2005 | B1 | 
| 6902524 | Alferness et al. | Jun 2005 | B2 | 
| 6908426 | Shapland et al. | Jun 2005 | B2 | 
| 7155295 | Lau et al. | Dec 2006 | B2 | 
| 20010029314 | Alferness et al. | Oct 2001 | A1 | 
| 20010047122 | Vanden Hoek et al. | Nov 2001 | A1 | 
| 20020007216 | Melvin | Jan 2002 | A1 | 
| 20020022880 | Melvin | Feb 2002 | A1 | 
| 20020068849 | Schweich, Jr. et al. | Jun 2002 | A1 | 
| 20020077524 | Schweich, Jr. et al. | Jun 2002 | A1 | 
| 20020082647 | Alferness et al. | Jun 2002 | A1 | 
| 20020091296 | Alferness | Jul 2002 | A1 | 
| 20020103511 | Alferness et al. | Aug 2002 | A1 | 
| 20030004547 | Owen et al. | Jan 2003 | A1 | 
| 20030060674 | Gifford, III et al. | Mar 2003 | A1 | 
| 20030060677 | French et al. | Mar 2003 | A1 | 
| 20030060895 | French et al. | Mar 2003 | A1 | 
| 20030199733 | Shapland et al. | Oct 2003 | A1 | 
| 20030199955 | Struble et al. | Oct 2003 | A1 | 
| 20030229265 | Girard et al. | Dec 2003 | A1 | 
| 20040133069 | Shapland et al. | Jul 2004 | A1 | 
| 20040171907 | Alferness et al. | Sep 2004 | A1 | 
| 20040171908 | Alferness et al. | Sep 2004 | A1 | 
| 20050059854 | Hoek et al. | Mar 2005 | A1 | 
| 20050085688 | Girard et al. | Apr 2005 | A1 | 
| 20050137673 | Lau et al. | Jun 2005 | A1 | 
| Number | Date | Country | 
|---|---|---|
| 3831 540 | Apr 1989 | DE | 
| 38 31 540 | Jun 1993 | DE | 
| 295 17 393 | Mar 1996 | DE | 
| 0 370 931 | May 1990 | EP | 
| 0 280 564 | Jun 1993 | EP | 
| 0 583 012 | Jul 1996 | EP | 
| 0 791 330 | Aug 1997 | EP | 
| 0 919 193 | Jun 1999 | EP | 
| 2 527 435 | Dec 1983 | FR | 
| 2 645 739 | Oct 1990 | FR | 
| 2 115 287 | Sep 1983 | GB | 
| 2 209 678 | May 1989 | GB | 
| 60-203250 | Oct 1985 | JP | 
| 1-145066 | Jun 1989 | JP | 
| 1-271829 | Oct 1989 | JP | 
| 1009457 | Apr 1983 | SU | 
| 1734767 | May 1992 | SU | 
| WO 9119465 | Dec 1991 | WO | 
| WO 9506447 | Mar 1995 | WO | 
| WO 9604852 | Feb 1996 | WO | 
| WO 9640356 | Dec 1996 | WO | 
| WO 9720505 | Jun 1997 | WO | 
| WO 9724101 | Jul 1997 | WO | 
| WO 9803213 | Jan 1998 | WO | 
| WO 9814136 | Apr 1998 | WO | 
| WO 9826738 | Jun 1998 | WO | 
| WO 9829041 | Jul 1998 | WO | 
| WO 9858598 | Dec 1998 | WO | 
| WO 0002500 | Jan 1999 | WO | 
| WO 9911201 | Mar 1999 | WO | 
| WO 9930647 | Jun 1999 | WO | 
| WO 9944534 | Sep 1999 | WO | 
| WO 9944680 | Sep 1999 | WO | 
| WO 9953977 | Oct 1999 | WO | 
| WO 9956655 | Nov 1999 | WO | 
| WO 0006026 | Feb 2000 | WO | 
| WO 0006027 | Feb 2000 | WO | 
| WO 0006028 | Feb 2000 | WO | 
| WO 0013722 | Mar 2000 | WO | 
| WO 0016700 | Mar 2000 | WO | 
| WO 0018320 | Apr 2000 | WO | 
| WO 0028912 | May 2000 | WO | 
| WO 0028918 | May 2000 | WO | 
| WO 0036995 | Jun 2000 | WO | 
| WO 0042919 | Jul 2000 | WO | 
| WO 0045735 | Aug 2000 | WO | 
| WO 0048795 | Aug 2000 | WO | 
| WO 0062727 | Oct 2000 | WO | 
| WO 0074769 | Dec 2000 | WO | 
| WO 0117437 | Mar 2001 | WO | 
| WO 0121098 | Mar 2001 | WO | 
| WO 0150981 | Jul 2001 | WO | 
| WO 0167985 | Sep 2001 | WO | 
| WO 0185061 | Nov 2001 | WO | 
| WO 0191667 | Dec 2001 | WO | 
| WO 0195830 | Dec 2001 | WO | 
| WO 0195831 | Dec 2001 | WO | 
| WO 0195832 | Dec 2001 | WO | 
| WO 0213726 | Feb 2002 | WO | 
| WO 0219917 | Mar 2002 | WO | 
| WO 03026483 | Apr 2003 | WO | 
| WO 03026484 | Apr 2003 | WO | 
| WO 03026485 | Apr 2003 | WO | 
| Number | Date | Country | |
|---|---|---|---|
| 20070027516 A1 | Feb 2007 | US |